Your browser doesn't support javascript.
Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants.
Agudelo, Marianna; Muecksch, Frauke; Schaefer-Babajew, Dennis; Cho, Alice; DaSilva, Justin; Bednarski, Eva; Ramos, Victor; Oliveira, Thiago Y; Cipolla, Melissa; Gazumyan, Anna; Zong, Shuai; Rodrigues, Danielle A S; Lira, Guilherme S; Conde, Luciana; Aguiar, Renato Santana; Ferreira, Orlando C; Tanuri, Amilcar; Affonso, Katia C; Galliez, Rafael M; Castineiras, Terezinha Marta Pereira Pinto; Echevarria-Lima, Juliana; Bozza, Marcelo Torres; Vale, Andre M; Bieniasz, Paul D; Hatziioannou, Theodora; Nussenzweig, Michel C.
  • Agudelo M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
  • Muecksch F; Laboratory of Retrovirology, The Rockefeller University, New York, NY.
  • Schaefer-Babajew D; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
  • Cho A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
  • DaSilva J; Laboratory of Retrovirology, The Rockefeller University, New York, NY.
  • Bednarski E; Laboratory of Retrovirology, The Rockefeller University, New York, NY.
  • Ramos V; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
  • Oliveira TY; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
  • Cipolla M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
  • Gazumyan A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
  • Zong S; Howard Hughes Medical Institute, The Rockefeller University, New York, NY.
  • Rodrigues DAS; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
  • Lira GS; Laboratório de Biologia de Linfócitos, Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Conde L; Departamento de Imunologia, Instituto de Microbiologia Paulo de Goes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Aguiar RS; Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Ferreira OC; Laboratório de Biologia de Linfócitos, Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Tanuri A; Departamento de Genética, Ecologia e Evolução, Insituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Affonso KC; Laboratório de Virologia Molecular, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Galliez RM; Laboratório de Virologia Molecular, Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Castineiras TMPP; Núcleo de Vigilância Hospitalar, Hospital Federal do Andaraí, Ministério de Saúde, Rio de Janeiro, Brazil.
  • Echevarria-Lima J; Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Bozza MT; Departamento de Doenças Infecciosas e Parasitárias, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Vale AM; Departamento de Imunologia, Instituto de Microbiologia Paulo de Goes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Bieniasz PD; Departamento de Imunologia, Instituto de Microbiologia Paulo de Goes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Hatziioannou T; Laboratório de Biologia de Linfócitos, Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Nussenzweig MC; Laboratory of Retrovirology, The Rockefeller University, New York, NY.
J Exp Med ; 219(9)2022 09 05.
Article in English | MEDLINE | ID: covidwho-1922148
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a global problem in part because of the emergence of variants of concern that evade neutralization by antibodies elicited by prior infection or vaccination. Here we report on human neutralizing antibody and memory responses to the Gamma variant in a cohort of hospitalized individuals. Plasma from infected individuals potently neutralized viruses pseudotyped with Gamma SARS-CoV-2 spike protein, but neutralizing activity against Wuhan-Hu-1-1, Beta, Delta, or Omicron was significantly lower. Monoclonal antibodies from memory B cells also neutralized Gamma and Beta pseudoviruses more effectively than Wuhan-Hu-1. 69% and 34% of Gamma-neutralizing antibodies failed to neutralize Delta or Wuhan-Hu-1. Although Class 1 and 2 antibodies dominate the response to Wuhan-Hu-1 or Beta, 54% of antibodies elicited by Gamma infection recognized Class 3 epitopes. The results have implications for variant-specific vaccines and infections, suggesting that exposure to variants generally provides more limited protection to other variants.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Year: 2022 Document Type: Article